JP7596296B2 - 炎症性障害を治療するための化合物および方法 - Google Patents

炎症性障害を治療するための化合物および方法 Download PDF

Info

Publication number
JP7596296B2
JP7596296B2 JP2021559994A JP2021559994A JP7596296B2 JP 7596296 B2 JP7596296 B2 JP 7596296B2 JP 2021559994 A JP2021559994 A JP 2021559994A JP 2021559994 A JP2021559994 A JP 2021559994A JP 7596296 B2 JP7596296 B2 JP 7596296B2
Authority
JP
Japan
Prior art keywords
compound
compounds
ibu
administered
doi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527401A (ja
JP2022527401A5 (https=
Inventor
チャールズ ディー． ニコルズ
ジェラルド ビラック
デイビッド イー． ニコルズ
Original Assignee
ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ filed Critical ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ
Publication of JP2022527401A publication Critical patent/JP2022527401A/ja
Publication of JP2022527401A5 publication Critical patent/JP2022527401A5/ja
Application granted granted Critical
Publication of JP7596296B2 publication Critical patent/JP7596296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2021559994A 2019-04-12 2020-04-13 炎症性障害を治療するための化合物および方法 Active JP7596296B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833140P 2019-04-12 2019-04-12
US62/833,140 2019-04-12
PCT/US2020/027981 WO2020210823A1 (en) 2019-04-12 2020-04-13 Compounds and methods for treating inflammatory disorders

Publications (3)

Publication Number Publication Date
JP2022527401A JP2022527401A (ja) 2022-06-01
JP2022527401A5 JP2022527401A5 (https=) 2023-04-20
JP7596296B2 true JP7596296B2 (ja) 2024-12-09

Family

ID=72751451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559994A Active JP7596296B2 (ja) 2019-04-12 2020-04-13 炎症性障害を治療するための化合物および方法

Country Status (9)

Country Link
US (2) US12398093B2 (https=)
EP (2) EP3952851B1 (https=)
JP (1) JP7596296B2 (https=)
KR (1) KR20220008264A (https=)
CN (2) CN113784709B (https=)
AU (1) AU2020271915B2 (https=)
BR (1) BR112021020424A2 (https=)
CA (1) CA3136153A1 (https=)
WO (1) WO2020210823A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309842A (en) * 2021-07-26 2024-02-01 Univ Louisiana State Compounds and methods for treating situations where the response depends on 5-HT2
SE2151519A1 (en) 2021-12-10 2023-06-11 Amidea Sweden Ab 2-(2,5-dimethoxyphenyl)ethanamine and uses thereof
WO2024010765A1 (en) * 2022-07-05 2024-01-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions for treating 5-ht2 conditions and methods of using the same
WO2024191924A2 (en) * 2023-03-10 2024-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150025063A1 (en) 2005-07-28 2015-01-22 Duke University Antiparkinsonian Action of Phenylisopropylamines
US20180055791A1 (en) 2008-07-10 2018-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage serotonin 5-ht2a receptor agonist to suppress inflammation
WO2018204354A1 (en) 2017-05-01 2018-11-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to reduce pathogenesis
WO2019064031A1 (en) 2017-09-29 2019-04-04 GW Research Limited USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINES IN THE TREATMENT OF EPILEPSY

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2884962B1 (en) * 2012-08-17 2019-05-01 Smartek International LLC Preparation of desiccated liposomes for use in compressible delivery systems

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150025063A1 (en) 2005-07-28 2015-01-22 Duke University Antiparkinsonian Action of Phenylisopropylamines
US20180055791A1 (en) 2008-07-10 2018-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage serotonin 5-ht2a receptor agonist to suppress inflammation
WO2018204354A1 (en) 2017-05-01 2018-11-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to reduce pathogenesis
WO2019064031A1 (en) 2017-09-29 2019-04-04 GW Research Limited USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINES IN THE TREATMENT OF EPILEPSY

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry，2003年，11(18)，3861-3868
J. Med. Chem.，1990年，33(2)，687-702
Quantitative Structure-Activity Relationships，1997年，16(6)，447-458

Also Published As

Publication number Publication date
CN113784709B (zh) 2024-05-10
US20220119340A1 (en) 2022-04-21
EP4685135A3 (en) 2026-04-15
EP4685135A2 (en) 2026-01-28
KR20220008264A (ko) 2022-01-20
BR112021020424A2 (pt) 2021-12-21
JP2022527401A (ja) 2022-06-01
WO2020210823A1 (en) 2020-10-15
EP3952851B1 (en) 2025-12-03
EP3952851A4 (en) 2023-01-11
CA3136153A1 (en) 2020-10-15
AU2020271915A1 (en) 2021-11-04
US12398093B2 (en) 2025-08-26
CN113784709A (zh) 2021-12-10
AU2020271915B2 (en) 2025-10-09
EP3952851A1 (en) 2022-02-16
US20260070872A1 (en) 2026-03-12
CN118384143A (zh) 2024-07-26

Similar Documents

Publication Publication Date Title
JP7596296B2 (ja) 炎症性障害を治療するための化合物および方法
JP5196701B2 (ja) クロモリンナトリウムの経口投与用製剤
WO2017202274A1 (zh) 烟醇醚类衍生物、及其制法和药物组合物与用途
CN110305095A (zh) 色甘酸衍生物以及成像和治疗的相关方法
KR20090129414A (ko) 인플루엔자 치료제
EA037447B1 (ru) Способ лечения эозинофильных заболеваний
KR20240163771A (ko) Kv7 채널 활성화제 조성물 및 이의 사용 방법
JPH09506622A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノキサリン化合物
JPH09507219A (ja) α−２−アドレノセプター作動剤として有用な７−（２−イミダゾリニルアミノ）キノリン化合物
CA3176909A1 (en) Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
JPH09511483A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノリン化合物
JP2022542645A (ja) 眼障害の治療のための化合物
CA2369746A1 (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
WO2023134732A9 (en) Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids
US20240165077A1 (en) Compositions and methods for treating neurologic diseases
HK40056643A (en) Compounds and methods for treating inflammatory disorders
CN105592849A (zh) 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
JP2001500526A (ja) 粘液溶解剤としての２−メチル−チアゾリジン−２，４−ジカルボン酸の使用
US20250270205A1 (en) Compositions and methods for inhibiting trem-1
WO2005011674A1 (ja) 気管支喘息の予防及び／または治療剤
WO2025160538A1 (en) Compositions and methods for treating hair graying and loss associated with aging
JPH04506517A (ja) ３，３―ジ置換インドリンの鼻腔内投与
WO2002034251A1 (en) Treatment of asthma with lfm analogues
JP2000290198A (ja) 鼻腔抵抗上昇等の抑制剤
JPWO2005056009A1 (ja) 肺疾患治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230412

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241127

R150 Certificate of patent or registration of utility model

Ref document number: 7596296

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150